ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

From Despair to Discovery: AI Technology Fuels New Treatment for Young Girl’s Unique Genetic Disorder

By: Zexprwire

Aria is a 3 year old girl living with a unique version of mitochondrial disease, caused by a defective gene called LONP1. Faced with losing their child, her parents have developed cureLONP1.com to raise awareness and funds in order to discover treatments. 

Devon, UK, 21st June 2024, ZEX PR WIREAlthough estimates vary, mitochondrial disease affects approx. 1 in 5000 people. Aria was born with a mutation in one of her copies of the LONP1 gene which was spontaneous and not inherited, called de novo. Her parents were told that only 2 other children in the global record appear with a similar mutation of LONP1 and they had not survived till their second birthday. Mitochondrial disease has no cure and is life limiting. 

Aria’s parents launched the website www.curelonp1.com in an attempt to raise funds for vital research and treatment discovery as they are in a race against time as often children like Aria don’t survive long. 

Parent led research and treatment discovery is the new normal, when the patient group is so small. In Aria’s case it is just her, described as N=1. Traditionally, drug companies only target large cohorts which offer a return on their investment in research and development. 

Her parents explain that they are super excited to partner with Unravel Biosciences, a Harvard spinout founded by Dr Richard Novak. Unravel offer a bespoke drug repurposing screen which is powered by AI machine learning technology, originally developed by the Wyss Institute for Biologically Inspired Engineering. 

Their extensive knowledge spans a range of fields, such as computational drug discovery, innovative animal models, automated drug screening, and entrepreneurship. This diverse expertise is crucial in creating a new paradigm for drug development that lowers costs and reduces risks.

The family need donations in order to access this program which promises to fast track potential drug discovery from known compounds and FDA approved drugs which the AI can model against Aria’s specific gene mutation. 

Unravel is just one of the programs Aria’s parents hope to employ if they reach their fund raising targets. 

You can discover more about Aria and her cure journey over at www.curelonp1.com. If you are inspired to help Aria find treatment, you can donate if you can and share her story. 

Press Images

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.